Published on IRCCS materno infantile Burlo Garofolo (https://www.burlo.trieste.it)

Home > Printer-friendly > A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents with Erythropoietic Protoporphyria or X-Linked Protoporphyria

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents with Erythropoietic Protoporphyria or X-Linked Protoporphyria [1]

Tipo di studio: 
Studio clinico interventistico con farmaco
Specialita': 
Reumatologia e Immunologia clinica
Organigramma: 
Dipartimento di Pediatria
Descrizione: 
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents with Erythropoietic Protoporphyria or X-Linked Protoporphyria
Codice EUDRACT: 
/
Codice Protocollo: 
MT-7117-A-302
Acronimo: 
/
Natura dello studio: 
/
Monocentrico/Multicentrico: 
Multicentrico - IRCCS Burlo Garofolo Partner
Sperimentatore Responsabile: 
Dott.ssa Serena Pastore
Sponsor: 
/
Sesso paziente: 
Maschile - Femminile
Fascia di età paziente: 
Adolescenti (12-17 anni)
Arruolamento categorie vulnerabili: 
Pazienti
Status studio: 
aperto
Status arruolamento: 
concluso
contenuto aggiornato il 26/03/2025 - 09:57:01

Source URL: https://www.burlo.trieste.it/phase-3-multicenter-randomized-double-blind-placebo-controlled-study-evaluate-efficacy-safety-and-tolerability-mt-7117-adults

Collegamenti
[1] https://www.burlo.trieste.it/phase-3-multicenter-randomized-double-blind-placebo-controlled-study-evaluate-efficacy-safety-and-tolerability-mt-7117-adults